Home  |  Contact

Cellosaurus 451Lu (CVCL_6357)

Cell line name 451Lu
Synonyms 451LU; 451-LU; WM 451-Lu; WM-451Lu; WM-451LU; WM451Lu; WM451; WC00059; LU451; EST81
Accession CVCL_6357
Resource Identification Initiative To cite this cell line use: 451Lu (RRID:CVCL_6357)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: Wistar Institute melanoma cell line collection.
Doubling time: 72 hours (PubMed=2253310).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Transcriptome analysis.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 10->10,13, D5S818: 11,12->12, D7S820: 9,10->10 and FGA: 21->21,25.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (PubMed=18632627; PubMed=21156289; Wistar).
TP53 p.Tyr220Cys (c.659A>G) (PubMed=21156289).
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_7928 (WM164)
CVCL_AP83 (451Lu-BR)CVCL_DG54 (451Lu-MR)
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ESTDAB; Wistar

D7S8209,10 (ATCC; ESTDAB)
10 (Cosmic-CLP; Wistar)
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn

PubMed=2918552; DOI=10.1093/jnci/81.6.440
Iliopoulos D., Ernst C., Steplewski Z., Jambrosic J.A., Rodeck U., Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
J. Natl. Cancer Inst. 81:440-444(1989)

Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A., Baird J., Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.
In vitro properties of human melanoma cells metastatic in nude mice.
Cancer Res. 50:2296-2302(1990)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=2068080; DOI=10.1073/pnas.88.14.6028
Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Brown K.D., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

PubMed=23285177; DOI=10.1371/journal.pone.0052760
Schayowitz A., Bertenshaw G., Jeffries E., Schatz T., Cotton J., Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H., Schuchter L., Clark D.P.
Functional profiling of live melanoma samples using a novel automated platform.
PLoS ONE 7:E52760-E52760(2012)

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cell line collections ATCC; CRL-2813 - Discontinued
Coriell; WC00059 - Discontinued
Cell line databases/resources CCLE; 451LU_NS
Cosmic-CLP; 1287706
GDSC; 1287706
Ontologies BTO; BTO:0003710
CLO; CLO_0001373
Biological sample resources BioSample; SAMN03471798
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM156019
GEO; GSM188238
GEO; GSM188268
GEO; GSM188327
GEO; GSM555187
GEO; GSM952579
GEO; GSM1199178
GEO; GSM1669568
Other Wikidata; Q54603178
Polymorphism and mutation databases Cosmic; 686411
Cosmic; 1047656
Cosmic; 1155281
Cosmic; 1155568
Cosmic; 1187587
Cosmic; 1303027
Cosmic; 2163808
Cosmic; 2230114